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Omnitrope is the ﬁrst Subsequent Entry Biologic (SEB)/Similar Biotherapeutic Product (SBP) ﬁled with
Health Canada, for purposes of marketing. Health Canada is the home organization of the Regulatory
Authority in Canada. As the ﬁrst SEB to be ﬁled for actual review, it presented unique challenges. While
the principles for the review and approval of a SEB were laid out in a “fact sheet” there remained still
a guidance to be drafted. The review of the submissions proceeded in parallel with the development of
the guideline. This article will provide the details of how the ﬁnal decision was arrived at and how that
decision validated the principles underlying the guidance document, in the absence of direct regulations
speciﬁcally addressing SEBs in Canada.
Crown Copyright  2011 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
With the expiry of patents for biologic therapeutic products that
areexpensive, there is an increaseddemand, onthepartofhealthcare
systems and the public, for more affordable medicines. Canada is no
exception to the need for developing andmarketingmore affordable
products. As a result, Health Canada (HC) started to receive enquiries
about the possibility of ﬁling Subsequent Entry Biologic products
(called SEBs in Canada), also called SBP (according to the WHO
nomenclature), biosimilars or follow-onproteinproducts. Thevariety
of names is due to the fact that the nomenclature is region and
jurisdiction-speciﬁc at this time, but the challenges faced by regula-
tors are similar, if not virtually identical, in all jurisdictions. In
developing an overall guideline that applies to SEBs-SBPs principles,
which were already in existence at the time of drafting of a “fact
sheet”, were further developed in the guidance document. At the
same time, the submission of an SEB application served to illustrate
andvalidate theprinciples thatHealthCanadahad intended to follow.
The principles utilized in the development of the guidelines are
partly based on current regulations and partly based on the science
underlying the development of biological therapeutic products.
These principles exist within the regulatory frameworks for bio-
logics, pharmaceuticals and generic pharmaceuticals drugs. SEBs
are considered to be “New Drugs” in Canada. As with any other
product, the onus is on the sponsor to provide the necessary
evidence to support all aspects of an application for marketevier Ltd. Open access under CC BY-Nauthorization. Furthermore, the approach applies only to those
SEBs that can be considered to bewell-characterized biologics, such
as human growth hormone, erythropoietins, granulocyte colony
stimulating factor (G-CSF) etc.
Part C, Division 8 of the Food and Drugs Regulations, deﬁne the
requirements for New Drug Submissions. The regulations do not
deﬁne precisely what information ought to be contained in the
submission, only that substantial evidence of safety and efﬁcacy is
required. This allows ﬂexibility for the regulator to adapt the
requirements, to the needed circumstance and situation, based on
reasonable science. For the speciﬁc case of SEBs/SBPs, this means
that a reduced data package, consisting of information on the
quality and comparability of the product to a suitable Reference
Biologic Product (RBP) could be deﬁned, based on the extent of the
knowledge on the RBP chosen. The Directions for Use, the Product
Monograph in Canada, for the SEB/SBP would have to describe the
basis on which the market authorization had been granted.
Other provisions considered included the following: SEBs will be
authorized based only on a submission that makes a direct
comparison to an innovator product, previously authorized for sale
in Canada. All the laws, patents and intellectual property principles
outlined in the applicable regulations apply. The applicable regu-
lations include, in addition to the Food and Drug Regulations as
noted above, Data Protection provision and Patented Medicine
Regulations. These provisions contain a prohibition to the use of an
innovator product as a comparator for 8 years after market
authorization has been given to the innovator drug. In addition, no
submission can be ﬁled for 6 years following market approval that
compares a product, directly or indirectly, to the innovative drug.C-ND license.
A.V. Klein / Biologicals 39 (2011) 278e281 279Once an SEB is authorized for sale, it is considered to be a stand-
alone product and is subject to the same life-cycle approach to
regulations, as all other products.
Authorization of an SEB is not considered a declaration of
pharmaceutical and/or therapeutic equivalence. The SEB will not
automatically be granted all of the indications of the comparator.
In conducting the review of the ﬁrst SEB, the following elements
were considered in decision-making [1]:
- Acceptability of the reference product and bio-similarity.
- Clinical data package and indications intended to be claimed.
- Endpoints and analysis of outcomes.
- Product Monograph/Package Insert/Labelling.
-Intercheangeability? Substitutability?
Other matters that required consideration were:
- the fears of the innovator industry: their concerns were
deferred initially, but allayed during consultations that took
place during both the drafting and the completion of the
guidance document, and
- the concerns expressed by the health care system, as these
products and the approach taken to their review and market
authorization were new to Canadian Provinces. Ultimately,
several of them decided to use the case of the ﬁrst SEB
authorized for market in Canada as a pilot project in their
deliberations to add SEBs to Provincial Formularies.2. Case study
Human Growth Hormone (HGH) is one of the early biologics
marketed in Canada. While originally it was extracted from human
pituitaries, it soon began to be produced as a recombinant product
in E. coli. At the time of submission of SEB application for HGH by
Sandoz, 7, or more, different brands of growth hormone were
authorized for market (although not all were marketed) and
a guideline for SEBs was in the initial phases of its drafting.
Therefore, the submission for Omnitrope was used, not only to
authorize the ﬁrst similar biological product, but also to gain the
experience needed to validate the concepts and principles behind
SEBs.
Omnitrope was ﬁled to be marketed as a powder for solution in
the following strengths: 5.8 mg/vial; 5 mg/1.5 mL and 10mg/1.5 mL
and intended for administration by the subcutaneous route. The
submission was ﬁled under the current New Drug Submission
Regulations for a multiplicity of indications authorized for the
entire group of marketed human growth hormones, including
those for which the RBP, Genotropin was also authorized:
- For the long-term treatment of children with GH failure; no
other causes of short stature
- Long-term replacement of HGH, in adults with GH deﬁciency
who were growth deﬁcient in childhood
Initially, the submissionwas rejectedwith a Notice of Deﬁciency,
because it was not reviewable for several reasons. The most
prominent reason was that the comparator or the Reference Bio-
logic Product (RBP), Genotropin, had never been marketed in
Canada. However, the sponsor re-ﬁled after three months with an
acceptable dossier. The number of indications and uses for Omni-
trope was still beyond the ones authorized for the comparator. The
sponsor was requested to withdraw the indications that were
beyond those of those authorized for Genotropin. Following with-
drawal of the excess indications, the review proceeded.The use of an authorized, but never marketed RBP, led to much
discussion and controversy. A number of issues needed to be
resolved so that any approach that would be ultimately taken in
accepting an authorized, but never marketed product, would not
result in inconsistencies in the requirements between those for
a biological versus those for a pharmaceutical agent, and that
unwarranted legal precedents would not be generated. Following
internal consultations, it was ﬁnally decided that Genotropinwould
be acceptable as an RBP and that Omnitrope would be reviewed
because it was in line with the principles and provisions of the
Canadian SEB Guidance document, for the following reasons:
- The use of Genotropinwas in line (certainly not contrary) to the
principles set out for comparators for SEBs.
- The size of the Canadian market which required that some
ﬂexibility be exercised, thus ensuring that an SEB would reach
the Canadian market.
- The need to use this ﬁrst submission as a learning situation, in
the absence of safe haven provisions in the regulations, similar
to those used in the USA. (Safe haven provisions allow sponsors
to ﬁle submissions with the regulator who, in turn, would
review the ﬁle, without penalty to the sponsor or without the
need to arrive at a regulatory decision, either positive or
negative).
- The packagewas extensive andwas determined to be complete
on screening.
- The submission was a solid package and contained complete
and solid data on the quality attributes of the proposed
product.
- There was a very extensive set of comparability studies
between the RBP and Omnitrope that demonstrated similarity
between the two products.2.1. Preclinical information: non-human data
- There were full Pharmacodynamic studies in the submission,
carried out in the rat. These studies conﬁrmed (by rat weight-
gain bioassay the pharmacodynamic properties of Omnitrope)
and by the rat tibia-width assay, the comparability of the
potency between Omnitrope and the RBP, Genotropin.
- While pharmacokinetic studies were not conducted, this was
considered acceptable at that time, as the need was eventually
balanced against the rest of the pre-clinical and clinical
information.
- The submission contained a reduced toxicology package: a 14
day toxicity study, no Genotoxicity studies, reproductive or
developmental toxicity study. This approach was considered
acceptable based on the ICH Guideline S6, applicable to bio-
logical drugs.
- Local tolerance to the sc injectionwas carried out in the rabbit;
there were no remarkable differences found between Omni-
trope and the RBP chosen. However, based on some local
reactions to the injection, rotation of injection sites is being
recommended.2.2. Clinical information: human data
2.2.1. Clinical basis for decision
There were four comparative Pharmacokinetic (PK) and Phar-
macodynamic (PD) studies [2]. These demonstrated bioequivalence
based on the approach and according to the requirements of the
Canadian Bioequivalence Guidelines. The parameters measured in
these studies were: ILGD-1 (Same as IGF-1 Insulin-like growth
A.V. Klein / Biologicals 39 (2011) 278e281280factor 1 also known as somatomedin C); IGFBP-3 (Insulin-like
growth factor-binding protein 3) and NEFA (Non-esteriﬁed fatty
acids in serum), and were all highly comparable between products
and formulations.
2.2.2. Efﬁcacy
- Efﬁcacy was supported by 5 Phase III clinical efﬁcacy and safety
studies; these were three sequential studies of Omnitrope
versus the RBP, of which three were sequential studies of
Omnitrope versus Genotropin involving liquid and powder
formulations, twice crossed over. They were designed as open-
label parallel studies, with patients being followed for over 15
months for long-term safety and efﬁcacy. These three studies
constituted, in reality, a single multiple cross-over trial that
enrolled 89 children.
- A fourth trial was carried out with Omnitrope, solution only: 50
children were followed for up to 30 months.
- A ﬁfth trial was carried out with Omnitrope powder dissolved
for injection: interim analyses were carried out at 12 and 24
months of HGH therapy.
Of the above, four studies were conducted in Poland and
Hungary (and the ﬁfth study was conducted in Spain.
Although the Guidelines for SEBs in Canada express a preference
for equivalence trials, the same guidelines also allow for some
ﬂexibility, if there is adequate evidence for the design and/or if theFig. 1. Design of the three consecutive Phase III studiessponsor justiﬁes the design chosen. Because this was the ﬁrst SEB
submitted to the regulator, and because there was a need to learn
by experience as the guideline was being drafted, additional ﬂexi-
bility was exercised in accepting a complex, non-conventional
cross-over study as the pivotal trial and that compared Omni-
trope to Genotropin as well as various formulations of Omnitrope,
to each other (Fig. 1).
In addition to the issues noted above regarding whether the
comparator could be used, the nature of the studies noted above,
and most notably, due to the standards used for growth assessment
which were Tanner or National growth standards, the submission
was rejected and ‘A Notice of Deﬁciency’ issued. When the
submission was re-ﬁled, the clinical studies on growth were re-
analysed according to CDC (American Centres for Disease Control)
standards. In the three sequential studies, the clinical efﬁcacy and
safety proﬁles were found to be comparable between Omnitrope
and the RBP, Genotropin, while in the other studies, Omnitrope
growth patterns were consisent with results from other studies
with HGH, conducted in children.
No trials were conducted in adults with Omnitrope. However,
consistent with the principle that the indications for a product
could be extrapolated on the basis of mechanistic and pathophys-
iological considerations, it was considered that the information
obtained from the trials in children might be suitable for extrapo-
lation to certain adult populations, in particular to adults with HGH
deﬁciency due to underlying hypothalamic or pituitary disease,
especially adults associated with HGH deﬁciency in childhood.EP2 K-99-PhIII/EP2K-00-PhIIIFo/EP2K-00-PhIIIAQ [3].
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- Safety considerations were based on the same studies as those
carried out for efﬁcacy purposes. The ﬁrst three sequential
studies were only analysed for the ﬁrst 9 months of treatment.
Adverse Events (AEs) seen in clinical trials were of the type and
nature of those already known for the RBP and other HGHs.
- The following AEs were reported: injection site reactions,
eosinophilia, headaches, increase of HgbA1c (glycosylated
haemoglobin used to follow diabetic control status), etc.
- There were interventions for the following AEs: hypothy-
roidism and headache. Hypothyroidism is commonly seen in
children with HGH deﬁciency, especially if due to pituitary or
hypothalamic disease, and is not surprising.
- Therewere two cases of worsening pre-existing scoliosis, a side
effect also seen with other growth hormone products.2.3. Labelling considerations
As with all new drugs, the labels relating to Omnitrope are
speciﬁc to the product. The label was considered to be both (class)
and product-speciﬁc, but without any mention of interchange-
ability or substitutability. Interchangeability and substitutability
are both under provincial jurisdiction in Canada and derive from
the authority of the Provinces to deliver health care. The package
insert, the Product Monograph in Canada includes speciﬁc mention
of the studies that formed the basis for the decision to authorize
Omnitrope for market.2.4. Post-market considerations
There were also post-market commitments required and these
included safety considerations and longer-term follow-up.3. Conclusions
Omnitrope was the ﬁrst SEB application ﬁled in Canada and its
contents constituted a good learning experience from the regu-
latory perspective. All the principles allowing the generation of
a well-characterized subsequent entry biological product were
considered in the regulatory review and the market authorization
of Omnitrope. Information and general knowledge from the
literature was leveraged to help decide on the acceptability of the
RBP and in shortening the development of the drug. The various
iterations in the review, with Notices of Deﬁciency and questions
posed to the sponsor clearly showed the direction that can be
taken in authorizing a SEB/SBP. The process also showed the
ﬂexibilities of the Canadian regulatory system and allowed for
a thorough evaluation of the quality considerations (compara-
bility analysis and determination), that were critical for the ﬁnal
decision.
The entire process underscored how solid science and rational
consideration can lead to logical and consistent regulatory
outcomes.
Conﬂict of interest
No potential conﬂicts of interest to disclose.
There is no conﬁdential information in this article.References
[1] Guidance for sponsors: information and submission requirements for subse-
quent entry biologics (SEBs). Health Canada, http://www.hc-sc.gc.ca/dhp-mps/
alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.
pdf; 2010 [Accessed on 18.04.11].
[2] Summary basis of decision, Omnitrope. Health Canada, http://www.hc-sc.gc.ca/
dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/
sbd_smd_2009_omnitrope_113380-eng.pdf; 2009 [Accessed on 18.04.11].
[3] Product monograph: Omnitrope, somatropin [rDNA origin] for injection.
Sandoz Canada Inc, http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang¼eng&
code¼81048; April 20 2009. Date of Authorization:.
